The U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) is seeking quotations for the development and production of genetically modified adeno-associated virus (AAV) particles which can be used to express a protein of interest.
AAV has been used to express proteins of interest in animal models for some time. The USAMRICD has a requirement to use this technology with a specific bioscavenger candidate of interest in support of countermeasure development.
The contractor shall provide all personnel, equipment, supplies, facilities, transportation, tools, materials, supervision, and other items and non-personal services necessary to perform the development of the genetically altered AAV virus particles as defined by USAMRICD.
Successful demonstration of the modified viral particle production will constitute the initial phase of the project with scaling of the process to allow the USAMRICD to order sufficient quantities for animal testing will comprise phase two.
The period of performance will be for one base year with two option years.
Further details are available under Solicitation Number: W81XWH-14-T-0467. The response deadline is September 16, 2014.